Spectrum of oncogenic driver mutations in lung adenocarcinomas from never smokers.

<p>From 202 tumors, 75.3% (152/202) harbored <i>EGFR</i> kinase domain mutations, 5.9% (12/202) <i>HER2</i> mutations, 5.0% (10/202) <i>ALK</i> fusions, and 2% (4/202) <i>KRAS</i> mutations, 1% (2/202) of tumors harbor <i>ROS1</i> fusion. There are 10.9% (22/202) with unknown oncogenic driver mutations.</p

Association between <i>EGFR</i> tyrosine kinase mutations and clinical pathological features.

<p>Association between <i>EGFR</i> tyrosine kinase mutations and clinical pathological features.</p

Detection of <i>CD74-ROS1</i> fusions in lung adenocarcinomas from never smokers.

<p>(A) Agarose gel electrophoresis analysis of RT-PCR products for <i>CD74</i>-<i>ROS1</i> fusions. E32, CD74-ROS1 exon 32 fusion; E34, CD74-ROS1 exon 34 fusion. (B) Sequencing of RT-PCR product from a tumor (No.72) identified a fusion of <i>CD74</i> exon 6 to <i>ROS1</i> exon 34. (C) Sequencing of RT-PCR product from a tumor (No.136) identified a fusion of <i>CD74</i> exon 6 to both <i>ROS1</i> exon 32 and exon 34.</p

Correlation Between <i>EGFR</i> Mutation Subtypes and Clinical Pathological Features.

<p>Correlation Between <i>EGFR</i> Mutation Subtypes and Clinical Pathological Features.</p

Comparison of clinical Characteristics of patients with or without known driver mutations.

<p>Comparison of clinical Characteristics of patients with or without known driver mutations.</p

Clinical Characteristics of Never Smokers With Lung Adenocarcinomas.

<p>Clinical Characteristics of Never Smokers With Lung Adenocarcinomas.</p

Detection of ROS1 mRNA levels in lung adenocarcinomas from never smokers either with indicated oncogenic driver mutations or negative for all known oncogenic driver mutations.

<p>Detection of ROS1 mRNA levels in lung adenocarcinomas from never smokers either with indicated oncogenic driver mutations or negative for all known oncogenic driver mutations.</p

Clinical information.

<p>XRT = Radiation therapy. A = Alive. D = Dead. NED = No evidence of disease. Survival in years from time of diagnosis. N/A = Not applicable. Note that cases CH34 and CH37 are recurrent tumors from the same patient.</p

Top Panels: CDKN2A immunohistochemistry.

<p>Representative chordoma cases showing lack of expression (left, CH39) and strong expression (right, CH35). Bottom Panels: PTEN Immunofluorescence. Representative chordoma cases were immunostained with anti-cytokeratin to highlight tumor cells (green) and anti-PTEN (red). Tumor cells show lack of PTEN expression in the left panel and expression of PTEN in the right panel. Note in both left panels that stromal tissue or normal cells show expression of CDKN2A and PTEN, but tumor areas indicated by arrows show lack of expression.</p

Chromosome 9 array CGH results.

<p>Array CGH results for chromosome 9 are shown for select chordoma cases showing homozygous <i>CDKN2A</i> deletion. Plots were generated with the Agilent Genomic Workbench Standard Edition 5.0 software. The sizes of the homozygous deletions for the five respective cases are as follows: 512 kb, 4.7 Mb, 76 kb, 76 kb, and 158 kb. Note that cases CH34 and CH37 are recurrent tumors from the same patient. Cases CH7 (158 kb) and CH36 (1.9 Mb) also harbor homozygous <i>CDKN2A</i> deletions and are not depicted above. kb = kilobases, Mb = megabases.</p